United Therapeutics CEO Martine Rothblatt Executes $5.19M Rule 10b5-1 Option Exercise and Sale

Executive Summary

On October 15, 2026, Dr. Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp ($UTHR), executed transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The transaction involved exercising stock options for 9,500 shares at an exercise price of $117.76 per share and selling the resulting 9,500 shares across multiple open-market tranches at weighted average prices ranging from $540.48 to $551.50 per share, generating aggregate proceeds of approximately $5.19 million.

Transaction Details

• Option Exercise: Exercised 9,500 stock options expiring on March 15, 2027, at a strike price of $117.76 per share ($1,118,720 cost basis).
• Open Market Sales: Disposed of 9,500 shares held indirectly through a family trust at an average price of ~$546.65, generating gross sale proceeds of $5,193,200.71.
• Remaining Holdings: Following the reported transactions, Dr. Rothblatt retains direct ownership of 40,513 shares, an additional 628,049 shares held across various family trusts, 166 shares held by spouse, and 223,910 derivative stock options expiring in March 2027.

Strategic Context & Significance

This transaction carries Medium significance due to the multi-million-dollar size, though its predictive signal regarding company performance is mitigated because it was conducted pursuant to an established Rule 10b5-1 trading plan. The plan provides for ongoing option exercises ahead of the March 2027 expiration date, representing standard equity compensation liquidation rather than a discretionary market-timing trade.